UCB expands immunology pipeline with 2.2 billion USD acquisition of Candid Therapeutics
UCB has entered into a definitive agreement to acquire clinical-stage biotech firm Candid Therapeutics for an upfront payment of $2 billion. The deal centers on cizutamig, a novel T-cell engager designed to reset the immune system in patients with severe autoimmune and inflammatory diseases.